



FARE[®]

Clinical Development Day

Ages and Stages of Food Allergy: Diagnosis and
Treatment Across the Lifespan

October 30–31, 2025

The Ronald Reagan Building and International Trade Center
Washington, D.C.

A Letter From the CEO of FARE

Welcome to Clinical Development Day! Thank you for joining us in Washington, D.C., for this important opportunity to discuss food allergy across the lifespan. My special thanks to our three Clinical Development Day co-chairs: Dr. Sarita Patil, of Harvard Medical School and Massachusetts General Hospital; Dr. Stephen Tilles, of the University of Washington (and FARE's Research and Strategic Innovation Advisor); and Dr. Yamini Virkud, of the University of North Carolina at Chapel Hill.



We also welcome you to the larger event, OctoberFARE, which places Clinical Development Day alongside FARE Neighborhoods Day, our Food Allergy Summit, and—special to this year—a spirited Teal Pumpkin Project Halloween “bash” for families on hand this Friday, October 31. We look forward to bringing participants for FARE Neighborhoods Day and Clinical Development Day together at shared tables for several meals.

FARE is committed to convening scientific dialogues that galvanize the community. In May of this year, FARE hosted the inaugural Mind Meld Innovation Summit at the Massachusetts Institute of Technology. This event gathered leading scientists and researchers to break down knowledge silos and boldly collaborate, working together to accelerate innovation in food allergy treatments and define the pathway to a cure for this disease.

We are also in the process of assembling the FARE Clinical Network “3.0,” our third cohort of sites—from large academic medical centers to local community clinics. For the first time, FARE is expanding the network to include higher education institutions representing complementary disciplines, all of which share the common goal of advancing the field of food allergy. Network membership is a prerequisite to apply for all future FARE funding and will serve as a channel for research opportunities.

Now in its fourth consecutive year, Clinical Development Day is critical to our collaborative leadership in food allergy innovation and to FARE's mission, which is to improve the quality of life and health for those with food allergy. We are grateful for your contributions to this conversation and your visionary energy. Let's go!

We Are FARE,

A handwritten signature in black ink that reads "Sung Poblete".

Sung Poblete, PhD, RN
CEO of FARE



The most up-to-date version of this agenda, as well as speaker information, can be accessed online and via your phone. **Please use the QR code to download the Cvent OctoberFARE event app!**

Agenda: Thursday, October 30, 2025

A Joint Dinner in Celebration of FARE Neighborhoods Day & Clinical Development Day

The dinner will take place in the Pavilion.

5:00 p.m.–5:30 p.m. **Cocktail Reception**

5:30 p.m.–5:35 p.m. **Welcome & Opening Remarks**

- Sung Poblete, PhD, RN, CEO of FARE

5:35 p.m.–7:00 p.m. **“Won’t You Be My Neighbor? Fostering Community Among All Food Allergy Voices”**

- Ben Zoldan, Founder, Storyleaders

7:00 p.m.–9:00 p.m. **Dinner**



Agenda: Friday, October 31, 2025

FARE's Clinical Development Day is a focused, one-day conference convening approximately 120 leaders in food allergy research, clinical care, regulatory science, and therapeutic development. Participants include academic investigators, practicing clinicians, representatives from the U.S. Food and Drug Administration (FDA) and National Institute of Allergy and Infectious Diseases (NIAID), biopharmaceutical and allergen product developers, and members of the investment community. The objective of the meeting is to facilitate open, cross-sector dialogue aimed at identifying actionable strategies to address persistent unmet needs in food allergy.

This year's theme—"Ages and Stages of Food Allergy: Diagnosis and Treatment Across the Lifespan"—emphasizes the need to better understand and respond to the evolving nature of food allergy. Particular attention will be given to the heterogeneity of disease expression, including age-related changes in phenotype that affect diagnosis, clinical management, and therapeutic development. We will also discuss underrecognized forms of food allergy, such as Alpha-gal syndrome (AGS), food protein-induced enterocolitis syndrome (FPIES), and eosinophilic esophagitis (EoE).

The agenda comprises six topic-focused sessions, each moderated by a conference co-chair. Sessions begin with a concise 10-minute didactic to frame the key issues, followed by an extended, moderated discussion. Panelists will represent a diversity of perspectives, but all attendees are encouraged to contribute actively. This highly interactive format is intended to foster substantive dialogue, break down traditional silos, and advance collaborative solutions that improve outcomes for individuals living with food allergy across the lifespan.

All sessions on October 31 take place in the Pavilion or adjacent foyer.

8:00 a.m.–8:45 a.m. **Breakfast & Recap**

- Ben Zoldan, Founder, Storyleaders

8:45 a.m.–9:00 a.m. **Networking**

9:00 a.m.–9:10 a.m. **Welcome & Opening Remarks**

- Stephen Tilles, MD, FARE and University of Washington
- Sarita Patil, MD, Harvard Medical School, Massachusetts General Hospital
- Yamini Virkud, MD, MA, MPH, University of North Carolina at Chapel Hill

9:10 a.m.–10:05 a.m.

Immune Diversity in Food Allergy: Age Matters, Innovation Depends on It

The clinical heterogeneity of food allergy—shaped by immune diversity and age-related changes—poses significant challenges for diagnosis and management. These complexities complicate the selection of appropriate regulatory and clinical development strategies. This session will examine how immune variation and age influence food allergy expression, the resulting challenges for product innovators, and potential approaches to address these issues.

- *Moderator:* Sarita Patil, MD

Didactics

Part 1: How Immune Phenotypes Differ with Age

- Wayne Shreffler, MD, PhD, Massachusetts General Hospital, Harvard Medical School

Part 2: Disease Heterogeneity and Its Impact on Innovation

- Hugh Sampson, MD, Icahn School of Medicine at Mount Sinai

Panel Discussion

- Joan Dunlap, MD, MHS, Johnson & Johnson
- Nancy Goodman, JD, MPP, Kids v Cancer

10:05 a.m.–10:50 a.m.

Feeding the Machine: The Next Generation of Food Allergy Diagnostics

Machine learning offers powerful tools for integrating complex datasets—ranging from omics and clinical data to environmental exposures—to better characterize immune responses and food allergy phenotypes. However, the path to accurate diagnosis is challenged by limited predictive value of current tests and challenges associated with test validation (e.g., disease heterogeneity, age-related phenotypic changes). This session will discuss both new diagnostics under development and how advanced data science can inform next-generation diagnostics, including what evidence is needed to overcome regulatory, scientific, and economic barriers to clinical adoption.

- *Moderator:* Yamini Virkud, MD, MA, MPH

Didactic

- Supinda Bunyavanich, MD, MPH, Phil, Icahn School of Medicine at Mount Sinai

Panel Discussion

- David Fleischer, MD, Children's Hospital Colorado
- Daniel Rotrosen, MD, Division of Allergy, Immunology, and Transplantation, NIAID, National Institutes of Health
- Alexandra Santos, MD, PhD, King's College London
- Erik Wambre, PhD, Icahn School of Medicine at Mount Sinai

10:50 a.m.–11:05 a.m.

Break

11:05 a.m.–12:00 p.m. **Underrecognized Food Allergies: Alpha-Gal, FPIES, EoE, and More**

As the food allergy epidemic grows, a range of underdiagnosed, food-induced immunologic disorders—including Alpha-gal (AGS) syndrome, food protein-induced enterocolitis syndrome (FPIES), eosinophilic esophagitis (EoE), and others—are gaining increased attention. These conditions present with distinct clinical features, immunologic mechanisms, and diagnostic challenges that fall outside traditional IgE-mediated paradigms. This session will highlight the unique barriers facing each of these syndromes, including gaps in awareness, delayed diagnosis, limited treatment options, and evolving regulatory frameworks. Through expert discussion, we will explore strategies to advance research, improve patient outcomes, and better integrate these conditions into the broader food allergy agenda.

- *Moderator:* Sarita Patil, MD

Didactic

- Anna Nowak-Wegrzyn, MD, PhD, NYU Langone

Panel Discussion

- Sara Anvari, MD, MSc, Baylor College of Medicine
- Scott Commins, MD, PhD, University of North Carolina at Chapel Hill
- Patricia Fulkerson, MD, PhD, Division of Allergy, Immunology and Transplantation, NIAID, National Institutes of Health
- Jennifer Maloney, MD, Regeneron
- Victoria Martin, MD, MPH, Mass General Brigham, Harvard Medical School
- Anubha Tripathi, MD, Center for Biologics Evaluation and Research, FDA

12:00 p.m.–12:45 p.m. **Sourcing Allergen as a Barrier to Optimal Food Allergy Diagnosis and Treatment**

Allergen characterization and standardization are foundational considerations in the development of food allergy diagnostics and therapies, yet sourcing and characterizing food allergens for clinical and research use remains challenging due to inherent source variability in protein content and component allergen potency. While pharmaceutical-grade, well-characterized allergens may be essential in certain therapeutic contexts, they may not be necessary—or practical—for all patients in real-world practice. This session will examine the scientific, regulatory, and logistical barriers to achieving allergen standardization, and explore how to prioritize standardization efforts where they matter most. By convening experts from research, industry, and regulatory sectors, the session will seek actionable strategies to support safe, scalable, and targeted use of food allergen materials.

- *Moderator:* Stephen Tilles, MD

Didactic

- Tibor Nemes, BS, Stallergenes Greer

Panel Discussion

- Shannon Brown, MS, HollisterStier Allergy
- Douglas Mack, MD, MSc, McMaster University
- Hendrik Nolte, MD, PhD, ALK-Abelló
- Ronald Rabin, MD, Center for Biologics Evaluation and Research, FDA

12:45 p.m.–1:45 p.m. **Group Photo & Lunch**

1:45 p.m.–2:50 p.m. **Immunotherapy, Biologics, and Beyond: Current Options and Future Directions in Food Allergy Treatment**

As therapeutic strategies for food allergy continue to evolve, new generations of biologics, immunotherapies, and novel interventions is advancing through industry-sponsored development programs. This session will provide an overview of current and emerging treatments, with discussion of how these innovations may be applied across different age groups and clinical phenotypes. Panelists will explore how disease heterogeneity, patient-specific factors, and real-world implementation challenges shape the future of food allergy management, offering both near-term insights and long-term perspectives on the treatment landscape.

- *Moderator:* Yamini Virkud, MD, MA, MPH

Didactic

- Edwin Kim, MD, University of North Carolina at Chapel Hill

Innovation Spotlights & Panel Discussion

- Jessica Grossman, MD, IgGennix
- Adam Miller, JD, MBA, AllerFund
- Samirkumar Patel, PhD, Moonlight Therapeutics, Inc.
- Sara Prickett, PhD, BSc, Aravax
- Brian Wong, MD, PhD, RAPT Therapeutics

2:50 p.m.–3:05 p.m. **Break**

3:05 p.m.–3:50 p.m.

Right Patient, Right Treatment—Even When It’s Hard: Ethics and Access in Food Allergy Management

As therapeutic options for food allergy expand, so too do the ethical and practical challenges of ensuring equitable, patient-centered care. This session will explore the complex intersection of access, ethics, and individualization in food allergy management. Topics will include health disparities in diagnosis and treatment access; the paradox of coverage; and the influence of financial incentives, conflicts of interest, and practice logistics on shared decision-making. Panelists will examine the real-world barriers to adopting current treatments—including the cost of biologics like omalizumab, the resource demands of oral immunotherapy (OIT), and the lack of regulatory approval for sublingual immunotherapy (SLIT) and other emerging approaches—and consider how to navigate these issues while prioritizing the right treatment for the right patient, even when it’s hard.

- *Moderator:* Stephen Tilles, MD

Didactic

- Pamela Guerrerio, MD, PhD, NIAID, National Institutes of Health

Panel Discussion

- Carla M. Davis, MD, Howard University
- Andrea Pappalardo Wlochowicz, MD, University of Illinois Chicago
- Marcus Shaker, MD, Dartmouth Geisel School of Medicine
- Richard Wasserman, MD, PhD, Medical City Children’s Hospital, Food Allergy Support Team
- Robert Wood, MD, Johns Hopkins University

3:50 p.m.–4:00 p.m.

Closing Remarks and Adjourn

- Stephen Tilles, MD, FARE and University of Washington

Biographies of Speakers

Sara Anvari, MD, MSc

Baylor College of Medicine

Dr. Sara Anvari is the Director of Clinical and Translational Research for the Texas Children's Hospital Food Allergy Program, where she has been a dedicated advocate for patients with food allergies. In this role, she has been instrumental in developing and advancing innovative food allergy clinical trials, bringing cutting-edge research and treatment options to Texas Children's Hospital.



With a deep commitment to the prevention and treatment of allergic and immunologic conditions, Dr. Anvari has established specialized clinics focused on food protein-induced enterocolitis syndrome (FPIES), eosinophilic gastrointestinal diseases (EGIDs) and drug allergy delabeling. Her work reflects a comprehensive approach to care, aiming to improve the quality of life for patients of all ages—from infants to adults.

Dr. Anvari leads a robust portfolio of clinical and basic science research projects that investigate IgE and non-IgE mediated food allergies. Her career has been dedicated to exploring the underlying immune mechanisms that drive these complex conditions. Through her research and clinical practice, Dr. Anvari remains committed to delivering exceptional, evidence-based care to patients and their families.

Shannon Brown, MS

HollisterStier Allergy

As Senior Manager for Research and Development at HollisterStier Allergy, Shannon Brown leads a team of scientists who are responsible for the technical aspects of allergenic products throughout their lifecycle. Research & Development works with a cross-functional team to support continuous process or product improvement initiatives—from execution of initial research and development, through process validation and troubleshooting support. Shannon and her team strive to improve scientific understanding of allergenic extracts through programs that focus on product characterization.



As a leader in the Scientific Affairs team, Shannon also gets involved in the evaluation of business opportunities and strategy development. She has over 20 years of experience in the allergenic products manufacturing business. Shannon has a BS in Biochemistry and an MS in Chemistry from Washington State University.

Supinda Bunyavanich, MD, MPH, MPhil

Icahn School of Medicine at Mount Sinai



Dr. Supinda Bunyavanich is the Mount Sinai Endowed Professor in Allergy and Systems Biology, Deputy Director of the Jaffe Food Allergy Institute, and a practicing Allergist/Immunologist at the Icahn School of Medicine at Mount Sinai. Professor Bunyavanich earned her BA summa cum laude from Harvard University, MD from Harvard Medical School, MPhil from the University of Cambridge, and MPH from the Harvard School of Public Health. She completed her internal medicine residency at Massachusetts General Hospital/Harvard Medical School, allergy/immunology fellowship at Brigham & Women's Hospital/Harvard Medical School, and a postdoctoral research fellowship at the Channing Division of Network Medicine, Harvard Medical School.

Dr. Bunyavanich's NIH-funded research group combines tools in epidemiology, multi-omics, and systems biology to elucidate and understand the pathobiology of asthma and allergic diseases. Dr. Bunyavanich also contributes as a leader and member of NIH/NIAID asthma and allergy research networks.

In addition to directing her research group at Mount Sinai, Dr. Bunyavanich provides patient care, teaches medical and graduate students, and mentors pre- and post-doctoral trainees. Dr. Bunyavanich has been a Nobel Conference Speaker, received the Harvard Shore Award, and is recognized as a Castle Connolly Exceptional Woman in Medicine.

Scott Commins, MD, PhD

University of North Carolina at Chapel Hill



Dr. Scott Commins is the Dr. William J. Yount Distinguished Professor at The University of North Carolina at Chapel Hill, where he is currently Vice Chief of the Division of Allergy, Immunology and Rheumatology in the Department of Medicine. Dr. Commins maintains an active clinical practice and research program, with a focus on alpha-gal syndrome and eosinophilic esophagitis. Scott is a member of the Food Allergy Initiative as well as the Institute for Global Health and Infectious Diseases at the University of North Carolina.

Carla M. Davis, MD

Howard University College of Medicine



Dr. Carla M. Davis received her undergraduate degree in Chemical Engineering from Howard University and her medical degree from Duke University. She completed her pediatrics residency and allergy/immunology fellowship at Baylor College of Medicine. She is the current Chair of Pediatrics and Child Health at Howard University College of Medicine.

Dr. Davis is focused on improving the quality of life for infants, children, and adolescents with allergic and immunologic diseases, most specifically food allergy, writing over 120 publications in the medical literature on these topics. She has been an NIH-funded investigator with expertise in translational research studies for assessment of clinical tolerance to allergic disease and the identification of clinical biomarkers. Her interest is the expansion of the current treatments through clinical trials and community educational and access initiatives. She has more than 20 years of experience in clinical care and performing clinical, educational, and translational research in allergic diseases and more than 5 years of experience in academic leadership and access initiatives.

She led legislative initiatives in school districts in Texas and published epidemiologic studies to define shellfish allergy.

Dr. Davis is the recent recipient of the Floyd Malveaux Award from the National Medical Association, awarded to individuals who have demonstrated excellence in research, education, and clinical practice in the areas of allergy and asthma. She is a leader on the American Academy of Allergy, Asthma, and Immunology executive committee. She is passionate about providing compassionate care to her patients and families.

Joan Dunlop, MD, MHS

Johnson & Johnson

Dr. Joan Dunlop is a Senior Medical Leader in the Dermatology and Respiratory Clinical Development group at Johnson and Johnson. In this role, she serves as medical lead for Phase 2 and 3 studies focused on asthma and atopic dermatitis.



A pediatric allergist/immunologist, Dr. Dunlop previously led the Phase 2 study of remibrutinib for peanut allergy at Novartis and is a drug developer with a deep passion for food allergy and other allergic diseases. She also holds a part-time appointment at the Johns Hopkins School of Medicine, where she continues to see patients in the Pediatric Allergy clinic.

Patricia Fulkerson, MD, PhD

National Institutes of Health (NIH)

Dr. Patricia Fulkerson is the Section Chief of the Food Allergy, Atopic Dermatitis, and Allergic Mechanisms Section of the Allergy, Asthma and Airway Biology Branch in the Division of Allergy, Immunology and Transplantation of the National Institute of Allergy and Infectious Diseases (NIAID), NIH.

Prior to joining the NIH, Dr. Fulkerson was an NIH-funded clinical investigator at Cincinnati Children's Hospital Medical Center with an independent research program focused on eosinophil development and a clinical practice focused on pediatric eosinophil-associated disorders.

Jessica Grossman, MD

IgGenix

Dr. Jessica Grossman is CEO of IgGenix, a clinical stage biotech company focused on antibody discovery and development. During her tenure at IgGenix she has raised over \$60 million in venture capital and readied an internally discovered antibody candidate to enter the clinic in just four short years in peanut allergy. Prior to IgGenix, she served as CEO of Medicines360, a global nonprofit drug company with a mission to expand access to essential medicines for all women.



As CEO, she increased revenue by 200% and raised \$20 million in non-dilutive capital for market expansion and product development. Previously, she served as founding President and CEO of Sense4Baby, Inc., raising a successful Series A venture round and then selling the company. Before Sense4Baby, she founded Gynesonics, and served as President, developing the strategic vision, building the company and successfully raising two rounds of venture capital financing. Dr. Grossman serves on the Board of Directors of Dare Biosciences. She holds 11 issued patents and has published several peer reviewed articles. She earned her MD degree at Thomas Jefferson University and her BAs in Biology and American Literature from Brandeis University.

Pamela Guerrero, MD, PhD

National Institute of Allergy & Infectious Disease (NIAID), National Institutes of Health (NIH)

Dr. Pamela Guerrero is currently Chief of the Food Allergy Research Section and the Laboratory of Allergic Diseases at NIH. Her research program is focused on understanding the genetic and immunologic mechanisms that lead to food allergy, eosinophilic esophagitis, and related diseases, and identifying strategies to improve the care of these patients.



Dr. Guerrero received her medical degree and doctorate in human genetics from Johns Hopkins University where she also completed a residency in pediatrics and fellowship in allergy and immunology.

Edwin Kim, MD

University of North Carolina at Chapel Hill

Dr. Edwin Kim is an Associate Professor of Pediatrics and Chief of the Pediatric Allergy and Immunology division at the University of North Carolina School of Medicine. He is also director of the UNC Food Allergy Initiative and Principal Investigator of the FARE Discovery Center of Distinction at UNC, whose focus is on the development of novel therapeutics for food allergy.



Douglas Mack, MD, MSc

McMaster University

Dr. Douglas Mack is a pediatric allergy, asthma, and immunology specialist and assistant clinical professor in the Department of Pediatrics at McMaster University. He is Vice President for the Canadian Society of Allergy and Clinical Immunology and Section of Allergy and Immunology Executive at the Ontario Medical Association. He is a co-author of clinical guidelines on the prevention of allergy, oral immunotherapy, and anaphylaxis and developed the first North American Manual on oral immunotherapy for food. He is an investigator in clinical trials for asthma, eczema, food allergy and epinephrine use. Dr. Mack is co-founder of Halton Pediatric Allergy clinic and Principal Investigator at Ontario Pediatric Allergy Research Corporation.



Jennifer Maloney, MD

Regeneron

Dr. Jennifer Maloney trained in pediatrics following medical school. Subsequently, she pursued an Allergy/Immunology fellowship at Mount Sinai School of Medicine in NYC. Jennifer remained on faculty within the Department of Pediatric Allergy at Mount Sinai following fellowship. While at Mount Sinai, the majority of her time was dedicated to food allergy research. From a clinical standpoint, Dr. Maloney was instrumental in the co-development of the Eosinophilic Esophagitis focused clinical practices, one of the first multi-disciplinary clinical practices specializing in the diagnosis and treatment of eosinophilic esophagitis in the NYC area.



Dr. Maloney transitioned to industry in 2007. She has predominantly worked within clinical development but has also held pharmacovigilance and global program head roles. Currently she is the therapeutic area lead for Immunology, Inflammation and Infectious Disease (I3). Dr. Maloney and her group are focused on bringing new medicines forward to treat allergic patients.

Victoria Martin, MD, MPH

Massachusetts General Brigham, Harvard Medical School

Dr. Victoria Martin, MD, MPH, is the Co-Director, GI Section, Food Allergy Center, Massachusetts General Hospital for Children; Associate Program Director, Fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition; and Assistant Professor in Pediatrics, Harvard Medical School.



Dr. Martin graduated from Harvard University with a degree in Biology. She completed her medical school and residency training in Pediatrics at the University of Massachusetts Medical School, and fellowship training at the Massachusetts General Hospital for Children in the division of Pediatric Gastroenterology and Nutrition. She also completed a master's degree in public health in Clinical Effectiveness at the Harvard School of Public Health.

Dr. Martin's clinical and research interests include the developing infant microbiome and its potential role in the development of gastrointestinal food allergic diseases. She leads the prospective 1000 infant cohort called "GMAP" and has led the thinking that non-IgE-mediated milk allergy in infants (aka FPIAP) is the first step on the atopic march. She is also actively studying its relationship to subsequent IgE-mediated food allergies as well as other gastrointestinal manifestations like FPIES and EoE.

Adam Miller

AllerFund

Adam Miller is a serial social entrepreneur and philanthropist dedicated to leveraging technology and innovation for social good. He founded Cornerstone OnDemand, growing it from his apartment into the world's largest educational technology company, empowering over 75 million people. Through 1P.org, Adam tackles pressing global challenges. He co-founded Better Angels to address homelessness in Los Angeles through scalable, community-driven solutions.

He also helped create 97Percent, a bipartisan organization working with gun owners to advance common-sense measures that reduce gun deaths. As Chairman of Team Rubicon (2013–2020), Adam helped grow it into a leading veterans service and disaster relief organization. He led the merger creating FARE, the world's largest food allergy nonprofit, and launched AllerFund, the first venture fund focused on food allergy innovation. Adam continues to drive impact through startups like Instil, which modernizes nonprofit operations, and Groundswell, which democratizes corporate giving. As Managing Partner of 1P Ventures, he invests in mission-driven tech companies. As a champion for LA's community, in addition to Better Angels, Adam founded LA-Tech.org and the 1,000 Interns Initiative. He lives in Los Angeles with his wife and three children.



Tibor Nemes, BS

Stallergenes Greer, Inc.



Mr. Tibor Nemes currently serves as Executive Vice President, Head of the Americas, and President of Stallergenes Greer, Inc. During his 25-year career in the biotech and pharmaceutical industry, he has held leadership positions with Novartis, Novavax, Bristol Myers Squibb, and Elan Pharmaceuticals. He has extensive technical experience in biopharmaceutical engineering, product development, quality assurance, and the manufacturing of biologics, vaccines, cyto-toxic oncology, and other sterile products. He has been involved in the commercialization of an array of biologics and vaccines throughout his career.

Mr. Nemes holds a bachelor's degree in chemical engineering from Pennsylvania State University and completed executive studies in leadership development from Harvard Business School.

Hendrick Nolte, MD, PhD

ALK-Abelló



Dr. Hendrick Nolte is Senior Vice President of clinical development of allergy immunotherapy tablets and other global drug developments for respiratory related products/projects for ALK-Abelló. Prior to this role, he led early and late stage respiratory and clinical research at Roche, Schering-Plough, and Merck. He also previously served as an associate professor of medicine at the University of Copenhagen.

Dr. Nolte has served on the U.S. Food and Drug Administration Vaccine Products Advisory Committee and on the Allergenic Products Advisory Committee. He has published extensively within the field of allergy and asthma with more than 200 peer-reviewed publications and given more than 1000 lectures at international meetings. He is a fellow of the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology.

He received his medical and postdoctoral degrees from the University of Copenhagen and is board-certified in pulmonology, internal medicine, and trained in allergy.

Anna Nowak-Wegrzyn, MD, PhD

New York University R. Grossman School of Medicine



Dr. Anna Nowak-Wegrzyn is a professor of Pediatrics at the New York University R. Grossman School of Medicine, the director of the Pediatric Allergy and Immunology Division, Department of Pediatrics, the Hassenfeld Children's Hospital, New York, NY, and the director of the FARE Clinical Network Food Allergy Center of Distinction at NYU. Her research interests focus on egg and milk allergies, baked milk and baked egg diets, food-induced anaphylaxis in children, novel diagnostic and therapeutic approaches to food allergy (oral, sublingual and patch immunotherapy), oral tolerance development, and in particular food protein-induced enterocolitis syndrome (FPIES).

Dr. Nowak-Wegrzyn has served as on the Board of Directors of the American Board of Allergy and Immunology (ABAI) since 2017. In 2022, she was elected to chair the ABAI board of directors. She serves as the chair of the Medical Advisory Board for the International FPIES Association and has led the international effort to write the first Consensus Guidelines for Diagnosis and Management of FPIES, published in 2017. She is associate editor for the Annals of Allergy, Asthma & Immunology, the official journal of the American College of Allergy, Asthma & Immunology. She completed her MD at Jagiellonian University and PhD at University of Warmia and Mazury.

Andrea Pappalardo Wlochowicz, MD

University of Illinois Chicago



Dr. Pappalardo is Associate Professor of Medicine and Pediatrics at the University of Illinois Chicago. She is board certified in three specialties: internal medicine, pediatrics and allergy/immunology and serves as the Allergy Service Director. Dr. Pappalardo recently served as the Medical Director for the Mobile Care Chicago Asthma Vans, where she provided school-based asthma and allergy subspecialty care throughout greater Chicago in front of schools. Her research focuses on school and community-engaged implementation science-driven interventions to reduce health disparities in asthma and food allergy.

She believes strongly in increasing sub-specialty access in historically marginalized populations in allergic diseases and in promoting health equity throughout the United States. Her work in stock inhaler legislation and programming is recognized locally and nationally.

Dr. Pappalardo attended medical school at the University of Illinois Chicago, followed by a combined internal medicine and pediatrics residency at the University of Chicago. She completed an allergy and immunology fellowship at Rush University Medical Center.

Samirkumar Patel, PhD

Moonlight Therapeutics, Inc.



Dr. Samirkumar Patel is an engineer who is currently co-founder and CEO of Moonlight Therapeutics. Moonlight Therapeutics is focused on improving the quality of life for people with food allergies by providing a patient-friendly treatment option. Moonlight's first treatment, MOON101, is designed to address peanut allergy. Prior to Moonlight Therapeutics, Dr. Patel was a co-founder of Clearside Biomedical (NASDAQ: CLSD). Clearside is an ophthalmic pharmaceutical company developing targeted therapies for ocular diseases. He invented the suprachoroidal technology that led to the creation of Clearside Biomedical and served as Director of Research. The company has an approved product, is in clinical trials in other indications with partners and completed an IPO in 2016. Prior to that he was at Georgia Institute of Technology where he obtained his doctoral degree in Chemical Engineering and focused on research using microneedles for ocular drug delivery. He worked for Alza Corporation (a J&J company) on controlled release oral drug products between his undergraduate and graduate degrees. Dr. Patel obtained a dual BS degree in Chemical and Material Science Engineering from University of California at Berkeley.

Sarita Patil, MD *(Co-Chair of Clinical Development Day)*

Harvard Medical School, Massachusetts General Hospital



Dr. Patil is an Assistant Professor at Harvard Medical School and an Assistant in Medicine at Massachusetts General Hospital (MGH). She is Co-Director of the MGH Adult Eosinophilic Esophagitis Clinic and a member of the MGH Food Allergy Center. Her laboratory, in the Center for Immunology and Inflammatory Diseases, focuses on understanding antibody and B cell responses in both the initiation and treatment of allergic diseases, with a particular focus on food allergies. She is the incoming co-chair of the 2026 Food Allergy Gordon Research Conference and Mechanistic Co-Chair of a trial sponsored by the Immune Tolerance Network.

Dr. Patil earned a bachelor's in human biology with honors from Stanford University and her medical degree from Duke University, which included a Howard Hughes Medical Research Fellowship. She completed her clinical training with an internal medicine residency at the University of Pennsylvania followed by an allergy and immunology fellowship at MGH.

Sara Prickett, PhD, BSc

Aravax



Dr. Sara Prickett has over 25 years' research experience in cellular immunology in the fields of Infection and Immunity and then Allergy, including 10 years within Biotech. She is a co-founder and Chief Scientific Officer of Aravax where she has overseen the transitioning of Aravax's peanut allergy peptide therapeutic from basic research into commercial development, through to Phase 2 trials. Prior to Aravax, Dr. Prickett held senior research posts at Alfred Health and Monash University (Australia) where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax.

Dr. Prickett received her Bachelor of Science from Sheffield University UK, and PhD from Imperial College, London, UK.

Ronald Rabin, MD

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration



Dr. Rabin is chief of the Laboratory of Immunobiochemistry (LIB), Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. Within the LIB, Dr. Rabin supervises the reference reagent laboratory to ensure proper potency measurements of standardized allergen extracts and the evaluation of "chemistry, manufacturing, and controls (CMC)" of allergenic products that are in clinical studies or under consideration for licensure. Additionally, Dr. Rabin was the primary clinical reviewer for the first sublingual immunotherapy products approved for grass and ragweed allergies.

Dr. Rabin received his medical degree at the University of South Florida College of Medicine, completed his residency in pediatrics at the University of Kentucky, and his fellowship in allergy and immunology at the National Institute of Allergy and Infectious Diseases.

Daniel Rotrosen, MD

DAIT/NIAID/National Institutes of Health

Dr. Daniel Rotrosen is the director of the NIAID Division of Allergy, Immunology and Transplantation (DAIT), one of the three extramural program divisions of the institute. Under his leadership the institute has promoted basic, translational, and clinical research to understand human immunology and to test novel approaches to treat and prevent allergic and autoimmune diseases and prevent rejection of lifesaving organ transplants.



Hugh Sampson, MD

Icahn School of Medicine at Mount Sinai

Dr. Hugh Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and director emeritus of the Jaffe Food Allergy Institute. Dr. Sampson's research interests have focused on food allergic disorders, and now include work on the pathogenesis of food-induced anaphylaxis, characterization of allergenic food proteins and their processing by the immune system, genetics of food allergy, development of novel diagnostic tests, and mechanisms of immunotherapeutic strategies for treating food allergies, including basic studies and clinical trials in oral, sublingual, and epicutaneous immunotherapy, and the potential use of biologics, such as anti-IgE and anti-cytokine monoclonal antibodies. He is the recipient of numerous grants from the National Institutes of Health, including the recently funded Exposure to Vaginal Microbiome in C-section Infants at High-risk for Allergies – A Pilot Study. Dr. Sampson supervises one clinic a week in pediatric allergy and is involved in teaching fellows and residents. He is past president of the American Academy of Allergy, Asthma & Immunology, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics, and a member of the National Academy of Medicine. He has authored more than 500 publications and has a current h-index of 154.



He received his medical degree from University at Buffalo School of Medicine, completed his pediatric residency at Northwestern University, and his allergy/immunology fellowship at Duke University.

Alexandra Santos, MD, PhD

King's College London

Dr. Alexandra Santos is Full Professor of Paediatric Allergy at King's College London and Honorary Consultant in Paediatric Allergy at the Evelina London Children's Hospital. Alexandra qualified in Medicine from the University of Coimbra, completed her training in Allergy and Clinical Immunology at Coimbra University Hospital and her PhD in Allergy and Immunology at King's College London, supervised by Professor Gideon Lack. Over the years, Dr. Santos has continued to combine clinical activity in Paediatric Allergy with clinical and laboratory translational research into food allergy.



The Santos Lab aims to improve the accuracy and safety of food allergy diagnosis and our understanding of the mechanisms of food allergy and oral tolerance in IgE-sensitised children to identify new targets for definitive treatment of food allergy. Alexandra has acted as chief investigator of many diagnostic studies in paediatric food allergy, including the FARE-funded Basophil Activation Test (BAT) Impact study, a multicentre randomized controlled trial on the integration of the BAT in clinical care in the UK.

Marcus Shaker, MD, MSc

Dartmouth Geisel School of Medicine

Dr. Marcus Shaker is a Professor of Pediatrics and of Medicine at the Dartmouth Geisel School of Medicine, and a member of the Allergy Immunology Joint Task Force on Practice Parameters. Dr. Shaker is also an Associate Editor of Annals of Allergy, Asthma, and Immunology and an Editorial Board member of The Journal of Allergy and Clinical Immunology: In Practice. Dr. Shaker's research interests center around optimizing value-based care in Allergy and Clinical Immunology. He has published over 200 articles and guidelines.



Dr. Shaker attended medical school at the University of Virginia and completed his pediatric residency and fellowship training in allergy and immunology, both at the University of Virginia Health System. He also holds a master's degree in evaluative clinical sciences and healthcare leadership.

Wayne Shreffler, MD, PhD

Massachusetts General Hospital, Harvard Medical School

Dr. Shreffler is Chief of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital (MGH), and an Investigator at the Center for Immunology and Inflammatory Disease as well as the Food Allergy Science Initiative. Since joining MGH in 2010, he has developed a highly integrated research and clinical program to better understand how adaptive immunity to dietary antigens is both naturally regulated and modulated by therapy in the context of food allergy.



Dr. Shreffler has authored more than 70 papers, maintained continuous research funding since 2007, served on the editorial board of The Journal of Allergy and Clinical Immunology and as a reviewer for numerous journals and grant study sections/committees. He was elected a Fellow of the American Academy of Allergy, Asthma & Immunology.

He received his medical and doctorate degrees from New York University and his Pediatrics training at the Albert Einstein College of Medicine. He completed his fellowship in Allergy & Immunology at the Mount Sinai School of Medicine.

Stephen Tilles, MD *(Co-Chair of Clinical Development Day)*

FARE and University of Washington

Dr. Stephen Tilles is a Board-Certified allergist, Clinical Professor at the University of Washington, and Founder of Advanced Allergy Insights LLC. He is FARE's Research and Strategic Innovation Advisor and also a consultant for Stallergenes Greer. His previous roles include 5 years as a pharma Medical Director with Aimmune Therapeutics, 23 years in Clinical Practice, and 18 years as Executive Director of ASTHMA Inc Clinical Research Center where he was Principal Investigator on more than 140 clinical trials. He is a former American Board of Allergy and Immunology member and past president of the American College of Allergy, Asthma & Immunology.



Anubha Tripathi, MD

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)



Dr. Tripathi conducts clinical review for FDA's Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Clinical and Toxicology Review, as a physician subspecialized in the field of allergy and clinical immunology. While her current role is primarily focused on the comprehensive evaluation of clinical development programs, including evaluation of safety and effectiveness data for investigational allergenic, vaccine, and related biological therapeutic products, she is also extensively involved in other aspects of this role. These include authoring publications in subspecialty medical journals and books including *Journal of Allergy and Clinical Immunology* and the *Encyclopedia of Food Allergy*; presenting to and discussing relevant regulatory information with various external subspecialty organizations including AAAAI, Paul Ehrlich Institute, Allergen Products Manufacturers' Association, and FARE; and aiding in the development of policy and of FDA workshops on various topics of importance to the field of allergy and clinical immunology.

After completing her residency training in internal medicine at Tufts Medical Center, Dr. Tripathi served as an attending physician in both hospital and medical practice settings. She completed her clinical and research fellowship in allergy and clinical immunology in the University of Virginia Health System's Division of Allergy and Clinical Immunology, where she also served on faculty as an Assistant Professor in Medicine. During her tenure, she served as both a principal, co-, and sub-investigator in clinical trials and research studies investigating various food allergies and eosinophilic esophagitis. She also authored several publications in these areas in various books and medical journals including *JACI* and *JACI: In Practice* and presented her research findings in these areas at the annual meetings of numerous medical subspecialty organizations including those of the American Academy of Asthma, Allergy, and Immunology, the American College of Asthma, Allergy & Immunology, the European Academy of Allergy & Clinical Immunology, and Digestive Disease Week.

Yamini Vikas Virkud, MD, MA, MPH *(Co-Chair of Clinical Development Day)*

University of North Carolina at Chapel Hill



Dr. Yamini Virkud is an assistant professor at the University of North Carolina at Chapel Hill (UNC) and adjunct faculty at Massachusetts General Hospital (MGH). She completed her medical training at Washington University in St. Louis and concurrently obtained a master's degree in biology and biomedical sciences at Washington University. She completed her residency in pediatrics at St. Louis Children's Hospital and trained at Duke University for her fellowship in allergy and immunology, where she researched under the mentorship of Dr. Wesley Burks, exploring the safety of peanut oral immunotherapy for food allergy. During this time, she also completed a clinical research fellowship at Duke Clinical Research Institute and a Master of Public Health in Biostatistics at UNC. From 2014 to 2021, she was a faculty member at MGH and Harvard Medical School and became the director of Biostatistics and Data Management core of the MGH Food Allergy Center. In 2021, she joined the UNC Food Allergy Initiative. Her research focuses on the phenotyping of different patients with food allergy and understanding the mechanisms of investigational therapies for food allergy.

Erik Wambre, PhD

Icahn School of Medicine at Mount Sinai

Dr. Erik Wambre is a Professor in the Department of Immunology and Immunotherapy and Director of Technology and Business Development at the Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai. He is also co-founder of OCCAM Immune; a non-profit Academic Research Organization spun out of HIMC that provides advanced immune monitoring solutions to industry and academic partners conducting clinical studies.



Dr. Wambre received his MSc in Biochemistry and Molecular Biology from the University of Lille, France, and a Master of Business Engineering from the School of Industrial Biology in Paris. He completed his PhD in Immunology summa cum laude from the University Paris Sorbonne, followed by postdoctoral training at the Benaroya Research Institute in Seattle, WA.

As a faculty member, Dr. Wambre's research focuses on the mechanisms that control the development and functional identity of pathogenic TH2 cells, and how these processes are altered during immunotherapy. His work bridges mechanistic immunology and translational research, with a strong emphasis on analyzing clinical trial samples. He has also pioneered advanced immunological tools and platforms to track antigen-specific immune responses and maximize data yield from limited biological material.

Richard Wasserman, MD, PhD

Medical City Children's Hospital, Food Allergy Support Team

Dr. Richard Wasserman is Medical Director of Pediatric Allergy and Immunology at Medical City Children's Hospital and Vice President of the Food Allergy Support Team.

An honors graduate of Hobart College, Dr. Wasserman received a PhD in immunology from Mt. Sinai School of Medicine and his MD from the University of Texas Southwestern Medical School (UTSWMS). Following training in pediatrics and fellowships in bone marrow transplantation and immunology at The Children's Hospital of Philadelphia, he became Chief of Pediatric Allergy and Immunology at UTSWMS, where he served on the faculty for 33 years and directed the Immunology Clinic for 19 years.



In 1988, Dr. Wasserman started a private practice in allergy/immunology and a research group that has conducted more than 130 FDA-approved studies. He has served as a member of the AAAAI Board of Directors and the Editorial Boards of JACI: In Practice, Annals of Allergy, Asthma and Immunology, Frontiers in Allergy, and the Journal of Food Allergy. He has co-authored more than 175 peer-reviewed publications, case reports, book chapters, and reviews.

Dr. Wasserman has been a leader in food allergy treatment. He co-founded the Food Allergy Support Team and has moderated the annual FAST food allergy treatment conferences.

Brian Wong, MD, PhD

RAPT Therapeutics

Dr. Brian Wong, President & CEO of RAPT Therapeutics, is a physician/scientist that brings to RAPT Therapeutics over 25 years of experience leading organizations at the forefront of innovative drug development. Prior to RAPT, he served as Senior Vice President, Research at Five Prime Therapeutics which was acquired by Amgen. Prior to Five Prime, Brian served as Director in the Inflammation Disease Biology Area at Roche. There, he led the discovery and supported the development of Roche's autoimmune disease portfolio, consisting of more than 20 biologics and small-molecule programs from discovery to late-stage clinical development and through approval.



Brian received his MD from the Weill Cornell Medical College and his PhD in Immunology from Rockefeller University.

Robert Wood, MD

Johns Hopkins University

Dr. Robert Wood is a professor of pediatrics at Johns Hopkins University School of Medicine and a professor of international health at the Johns Hopkins Bloomberg School of Public Health. An internationally recognized expert in food allergy and childhood asthma, Dr. Wood is chief of the Eudowood Division of Allergy and Immunology in the Johns Hopkins Children's Center. He also serves as director and attending physician of the Pediatric Allergy Clinics at The Johns Hopkins Hospital and as director of the Pediatric Allergy Consultation Service.



Dr. Wood is a world-renowned expert in food allergy and childhood asthma and has published more than 200 manuscripts in scientific journals, including The New England Journal of Medicine, JAMA, Pediatrics, and the Journal of Allergy and Clinical Immunology, as well as three books and numerous book chapters. He is associate editor of the Journal of Allergy and Clinical Immunology, deputy editor of the journal Pediatric Allergy and Immunology, and was previously an associate editor of the Annals of Allergy, Asthma & Immunology. He has served on the board of directors of the American Board of Allergy and Immunology and the American Academy of Allergy, Asthma & Immunology, where he held positions as secretary-treasurer and president-elect.

Dr. Wood earned his medical degree from the University of Rochester School of Medicine and Dentistry. He completed both a three-year pediatrics residency—serving as chief resident the final year—and a pediatric allergy and immunology fellowship at The Johns Hopkins Hospital. Dr. Wood joined the Johns Hopkins faculty in 1988.

Ben Zoldan

Storyleaders

Ben Zoldan is on a mission to re-humanize the way we work and lead. As the founder of Storyleaders, he helps leaders and teams tap into the human qualities: trust, courage, purpose, and connection, that fuel extraordinary results in a world dominated by AI and automation. Ben believes business is the greatest stage to unleash what makes us most human, and his work creates cultures where people thrive, collaborate deeply, and inspire change together.



Notes

[illegible]

Notes

With Thanks to FARE's Platinum Partner





FARE (Food Allergy Research & Education) is the leading nonprofit organization that empowers the food allergy patient across their journey of managing the disease. FARE delivers innovation by focusing on three strategic pillars—research, education, and advocacy. FARE's initiatives accelerate the future of food allergy through effective policies and legislation, novel strategies toward prevention, diagnosis, and treatment, and building awareness and community. For more information, visit **FoodAllergy.org**.

Follow FARE on social media!



Thank You to Our Generous Clinical Development Day Sponsors

